Atrium Therapeutics, Inc.
NASDAQ: RNA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kathleen Gallagher
- Employees
- 511
- Headquarters
- San Diego, United States
- IPO year
- 2026
- Market cap
- $219.1M
- Website
- http://www.atriumtherapeutics.com
Loading RNA…
Loading profile data…Frequently asked questions about RNA
What does Atrium Therapeutics, Inc. (RNA) do?
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 synd...
Where does RNA trade?
Atrium Therapeutics, Inc. (RNA) trades on the NASDAQ Global Select.
What sector is RNA in?
Atrium Therapeutics, Inc. (RNA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Atrium Therapeutics, Inc.?
Kathleen Gallagher is the chief executive officer of Atrium Therapeutics, Inc. (RNA).
Where is Atrium Therapeutics, Inc. headquartered?
Atrium Therapeutics, Inc. is headquartered in United States.
Does RNA pay a dividend?
Atrium Therapeutics, Inc. (RNA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RNA go public?
Atrium Therapeutics, Inc. (RNA) completed its initial public offering in 2026.